To access the call, participants may join via a live webcast on the Investors and News section of the
A replay of the conference call will be available for 90 days from the call and may be accessed in the Investors & News/Events and Presentations section on the
About
F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit https://www.f-star.com/ and follow us on LinkedIn and Twitter.
For further information, please contact:
For investor inquiries
VP Investor Relations
+1 240 543 7970
lindsey.trickett@f-star.com
For media inquiries
617-510-4373
Shik.Helen10@gmail.com
© OMX, source